BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 22818843)

  • 1. Diaphragmatic rupture, a new complication of Bevacizumab.
    Lacaze L; Scotté M
    Eur J Surg Oncol; 2012 Nov; 38(11):1079-81. PubMed ID: 22818843
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bevacizumab-associated fistula formation in postoperative colorectal cancer patients.
    Ganapathi AM; Westmoreland T; Tyler D; Mantyh CR
    J Am Coll Surg; 2012 Apr; 214(4):582-8; discussion 588-90. PubMed ID: 22321523
    [TBL] [Abstract][Full Text] [Related]  

  • 3. "Spontaneous," delayed colon and rectal anastomotic complications associated with bevacizumab therapy.
    August DA; Serrano D; Poplin E
    J Surg Oncol; 2008 Feb; 97(2):180-5. PubMed ID: 18095268
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Endoscopic management of colonic perforation owing to angiogenesis inhibitors.
    Ezzedine S; Bege T; Berdah S; Vitton V; Grimaud JC; Barthet M
    Surg Laparosc Endosc Percutan Tech; 2010 Dec; 20(6):e230-2. PubMed ID: 21150409
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Surgical management of bevacizumab-associated peritonitis due to perforation].
    Kube R; Meyer F; Bien N; Schmidt C; Mroczkowski P; Dalicho S; Lippert H
    Zentralbl Chir; 2009 Sep; 134(5):462-7. PubMed ID: 19757347
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Review: incidence and clinical significance of Bevacizumab-related non-surgical and surgical serious adverse events in metastatic colorectal cancer.
    Hompes D; Ruers T
    Eur J Surg Oncol; 2011 Sep; 37(9):737-46. PubMed ID: 21764243
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bevacizumab-induced bowel perforation.
    Sliesoraitis S; Tawfik B
    J Am Osteopath Assoc; 2011 Jul; 111(7):437-41. PubMed ID: 21803880
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical and radiological response with FOLFOXIRI and bevacizumab as third-line therapy after mFOLFOX6 and FOLFIRI failure.
    de Melo JV; Vieira de Melo MS; Abad MH
    Anticancer Drugs; 2011 Jun; 22 Suppl 2():S19-20. PubMed ID: 21768793
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Angiogenesis inhibition with bevacizumab and the surgical management of colorectal cancer.
    Thornton AD; Ravn P; Winslet M; Chester K
    Br J Surg; 2006 Dec; 93(12):1456-63. PubMed ID: 17115389
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies.
    Shih T; Lindley C
    Clin Ther; 2006 Nov; 28(11):1779-802. PubMed ID: 17212999
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Trials of bevacizumab in breast cancer--a safety review.
    Kümler I; Nielsen DL
    Expert Opin Drug Saf; 2012 May; 11 Suppl 1():S37-48. PubMed ID: 21663533
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Spontaneous nasal septal perforation with antiangiogenic bevacizumab therapy.
    Burkart CM; Grisel JJ; Hom DB
    Laryngoscope; 2008 Sep; 118(9):1539-41. PubMed ID: 18622319
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [A case of delayed colonic perforation after metallic stent placement for advanced descending colon cancer during bevacizumab-based chemotherapy].
    Tanaka I; Hisai H; Miyazaki E; Ono M; Maeda Y; Sato M; Kawasaki R; Gyobu H; Nakajima S; Yamada S; Muramatsu H
    Gan To Kagaku Ryoho; 2011 Nov; 38(12):2319-21. PubMed ID: 22202368
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Delayed bile leak with avastin after liver resection for metastatic colorectal cancer.
    Lordan JT; Wilkins M; Karanjia ND
    Hepatogastroenterology; 2011; 58(110-111):1769-70. PubMed ID: 22086700
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bevacizumab in lung cancer: lackluster performance and unjustified expense?
    Dasanu CA
    J Oncol Pharm Pract; 2012 Sep; 18(3):381-2. PubMed ID: 22777997
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Refractory generalized seizures as a possible side effect of bevacizumab in a colon cancer patient.
    Berk V; Ismailogullari S; Donmez H; Karaca H; Inanc M; Ozkan M
    Med Oncol; 2012 Jun; 29(2):1017-9. PubMed ID: 21461780
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acute and severe acne in a patient treated with bevacizumab.
    Molina-Ruiz AM; Domine M; Requena L
    Int J Dermatol; 2013 Apr; 52(4):486-90. PubMed ID: 23432695
    [TBL] [Abstract][Full Text] [Related]  

  • 18. GI perforation associated with bevacizumab.
    Yoon SS; Rivera R; Shah A; Ozden N
    Gastrointest Endosc; 2012 Jun; 75(6):1286-7. PubMed ID: 21862004
    [No Abstract]   [Full Text] [Related]  

  • 19. Phase 2 trial of maintenance bevacizumab alone after bevacizumab plus pemetrexed and carboplatin in advanced, nonsquamous nonsmall cell lung cancer.
    Stevenson JP; Langer CJ; Somer RA; Evans TL; Rajagopalan K; Krieger K; Jacobs-Small M; Dyanick N; Milcarek B; Coakley S; Walker S; Eaby-Sandy B; Hageboutros A
    Cancer; 2012 Nov; 118(22):5580-7. PubMed ID: 22544579
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bevacizumab: overview of the literature.
    Braghiroli MI; Sabbaga J; Hoff PM
    Expert Rev Anticancer Ther; 2012 May; 12(5):567-80. PubMed ID: 22594892
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.